Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biolectra Magnesium Forte is an oral dietary supplement and over-the-counter mineral preparation formulated as effervescent tablets containing magnesium oxide (equivalent to 243 mg of elemental magnesium). Originally developed by the German pharmaceutical company Hermes Arzneimittel and marketed in Portugal by Laboratórios Azevedos, it is indicated for the treatment and prevention of magnesium deficiency, particularly when associated with neuromuscular disorders, muscle tension, and calf cramps. Magnesium acts as a physiological calcium antagonist, blocking voltage-gated L-type calcium channels and NMDA receptors, thereby regulating muscle contraction, nerve conduction, and electrolyte balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biolectra Magnesium Forte.